StockData
Kymera Therapeutics, Inc. logo

Kymera Therapeutics, Inc. (KYMR) stock

KYMRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/30227% above fair value
$121.13−0.39 (-0.32%)

Close on Nov 18, 2026Market cap $10.34BP/E –Yield –

Kymera Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Kymera Therapeutics's operating income for the twelve months ending Sep 30, 2026 was -$404.89M. For fiscal 2025 it was -$349.40M. The highest annual figure on record is -$42.21M in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$349.40M–
FY2024Dec 31, 2024-$261.64M–
FY2023Dec 31, 2023-$165.53M–
FY2022Dec 31, 2022-$161.26M–
FY2021Dec 31, 2021-$100.53M–
FY2020Dec 31, 2020-$46.30M–
FY2019Dec 31, 2019-$42.21M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$147.23M–
Q2 FY2026Jun 30, 2026-$75.61M–
Q1 FY2026Mar 31, 2026-$84.15M–
Q4 FY2025Dec 31, 2025-$97.90M–
Q3 FY2025Sep 30, 2025-$92.52M–
Q2 FY2025Jun 30, 2025-$84.56M–
Q1 FY2025Mar 31, 2025-$74.43M–
Q4 FY2024Dec 31, 2024-$80.76M–
Q3 FY2024Sep 30, 2024-$72.12M–
Q2 FY2024Jun 30, 2024-$50.93M–
Q1 FY2024Mar 31, 2024-$57.83M–
Q4 FY2023Dec 31, 2023-$19.31M–
Q3 FY2023Sep 30, 2023-$57.51M–
Q2 FY2023Jun 30, 2023-$43.38M–
Q1 FY2023Mar 31, 2023-$45.33M–
Q4 FY2022Dec 31, 2022-$38.63M–
Q3 FY2022Sep 30, 2022-$44.88M–
Q2 FY2022Jun 30, 2022-$40.81M–
Q1 FY2022Mar 31, 2022-$36.93M–
Q4 FY2021Dec 31, 2021-$33.99M–
Q3 FY2021Sep 30, 2021-$28.64M–
Q2 FY2021Jun 30, 2021-$24.73M–
Q1 FY2021Mar 31, 2021-$13.17M–
Q4 FY2020Dec 31, 2020-$12.78M–
Q3 FY2020Sep 30, 2020-$8.08M–
Q2 FY2020Jun 30, 2020-$14.19M–
Q1 FY2020Mar 31, 2020-$11.25M–
Q4 FY2019Dec 31, 2019-$11.78M–
Q3 FY2019Sep 30, 2019-$11.86M–

More Kymera Therapeutics figures

See a number that looks wrong?